Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments, and Licenses (Details)

v2.4.0.8
Acquisitions, Investments, and Licenses (Details) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2013
Dec. 31, 2012
Mar. 04, 2013
Cytochroma acquisition [Member]
Summarizes the estimated fair value of the net assets acquired and liabilities      
Current assets (including cash of $378 thousand)     $ 1,224
Current Asset include cash     378
Intangible assets:      
In-process research and development     191,530
Patents     210
Total intangible assets   176,200 191,740
Goodwill 364,900   2,411
Property, plant and equipment     306
Accounts payable and accrued expenses     (1,069)
Total purchase price     $ 194,612